Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI)

ورودی‌های بالینی بیمار

حداقل ۱۸ — حداکثر ۱۰۰ • واحد: years

حداقل ۰ — حداکثر ۲۰۰۰ • واحد: cells/μL

حداقل ۰ — حداکثر ۷ • واحد: log10 copies/mL

حداقل ۵ — حداکثر ۲۰ • واحد: g/dL

حداقل ۱۰ — حداکثر ۱۰۰۰ • واحد: ×10³/μL

حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L

حداقل ۱۰ — حداکثر ۵۰۰ • واحد: U/L

حداقل ۰.۵ — حداکثر ۱۰ • واحد: mg/dL

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
vacs cci score
—percentage
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Low Risk0–25
  • Moderate Risk26–50
  • High Risk51–75
  • Very High Risk76–100
Direct Clinical Answer

The Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI) calculates predicting invasive bacterial infection probability and quantifying systemic host response to sepsis. Key inputs include age. Scores guide administering empiric broad-spectrum antimicrobial regimens, infectious source control, and isolation protocols. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Combines the Veterans Aging Cohort Study (VACS) Index with the Charlson Comorbidity Index to provide enhanced mortality risk prediction for patients with HIV. This integrated score incorporates HIV-specific biomarkers, general health indicators, and comprehensive comorbidity assessment to estimate 5-year all-cause mortality risk.

Clinical Indication

The Veterans Aging Cohort Study-Charlson Comorbidity Index (VACS-CCI) is indicated for bedside clinical practice to support Combines the Veterans Aging Cohort Study (VACS) Index with the Charlson Comorbidity Index to provide enhanced mortality risk prediction for patients with HIV. This integrated score incorporates HIV-specific biomarkers, general health indicators, and comprehensive comorbidity assessment to estimate 5-year all-cause mortality risk.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with suspected sepsis, meningitis, pneumonia, COVID-19, opportunistic infections, or fever of unknown origin. Clinical application is indicated across Infectious disease services, septic shock bays, febrile illness clinics, and isolation units.

Limitations & Contraindications

Timely administration of empiric antibiotic therapy in suspected septic shock must never be delayed for score tabulation.

Clinical Pearls & Action Plan

Blood and site-specific microbiological cultures should be secured prior to administering broad-spectrum antimicrobials.

Formula & Variables:

VACS-CCI = [(Linear Predictor + 2.5390222) / 10.6663937] × 100, where Linear Predictor combines VACS Index components (age, CD4, HIV RNA, hemoglobin, FIB-4, eGFR, HCV) with Charlson Comorbidity Index weighted scores

Input Parameters

NameTypeRequiredDescription
ageintegerYesPatient age in years(years)
sexstringYesPatient sex for accurate eGFR calculation
racestringYesPatient race for eGFR calculation (black race adjustment applied)
cd4_countintegerYesCD4 T-cell count in cells/μL, primary marker of HIV-related immunodeficiency(cells/μL)
hiv_rna_logfloatYesHIV-1 RNA viral load in log10 copies/mL, measures viral replication and treatment effectiveness(log10 copies/mL)
hemoglobinfloatYesHemoglobin level in g/dL, marker of anemia and overall health status(g/dL)
plateletsintegerYesPlatelet count in ×10³/μL, used in FIB-4 calculation for liver fibrosis assessment(×10³/μL)
astintegerYesAspartate aminotransferase in U/L, liver enzyme used in FIB-4 calculation(U/L)
altintegerYesAlanine aminotransferase in U/L, liver-specific enzyme used in FIB-4 calculation(U/L)
creatininefloatYesSerum creatinine in mg/dL, kidney function marker used for eGFR calculation(mg/dL)
hepatitis_cstringYesHepatitis C virus co-infection status
myocardial_infarctionstringYesHistory of myocardial infarction (Charlson Comorbidity Index component)
congestive_heart_failurestringYesHistory of congestive heart failure (Charlson Comorbidity Index component)
peripheral_vascular_diseasestringYesHistory of peripheral vascular disease (Charlson Comorbidity Index component)
cerebrovascular_diseasestringYesHistory of cerebrovascular disease/stroke (Charlson Comorbidity Index component)
dementiastringYesHistory of dementia (Charlson Comorbidity Index component)
chronic_pulmonary_diseasestringYesHistory of chronic pulmonary disease (Charlson Comorbidity Index component)
rheumatic_diseasestringYesHistory of rheumatic disease (Charlson Comorbidity Index component)
peptic_ulcer_diseasestringYesHistory of peptic ulcer disease (Charlson Comorbidity Index component)
mild_liver_diseasestringYesHistory of mild liver disease (Charlson Comorbidity Index component)
diabetesstringYesHistory of diabetes without complications (Charlson Comorbidity Index component)
diabetes_complicationsstringYesHistory of diabetes with complications (Charlson Comorbidity Index component)
hemiplegiastringYesHistory of hemiplegia or paraplegia (Charlson Comorbidity Index component)
renal_diseasestringYesHistory of moderate to severe renal disease (Charlson Comorbidity Index component)
any_malignancystringYesHistory of any malignancy including leukemia and lymphoma (Charlson Comorbidity Index component)
moderate_severe_liver_diseasestringYesHistory of moderate to severe liver disease (Charlson Comorbidity Index component)
metastatic_solid_tumorstringYesHistory of metastatic solid tumor (Charlson Comorbidity Index component)
aidsstringYesAIDS diagnosis (Charlson Comorbidity Index component)

Score Interpretation & Guidance

RangeStageDescription
0–25Low RiskLow mortality risk
26–50Moderate RiskModerate mortality risk
51–75High RiskHigh mortality risk
76–100Very High RiskVery high mortality risk

Evidence-Based References (EBM)

  • Justice AC, Lasky E, McGinnis KA, Skanderson M, Conigliaro J, Fultz SL, et al. Medical disease and alcohol use among veterans with human immunodeficiency infection: A comparison of disease measurement strategies. Med Care. 2006 Apr;44(4):S52-60. doi: 10.1097/01.mlr.0000208140.93199.44.DOI: 10.1097/01.mlr.0000208140.93199.44
  • McGinnis KA, Fultz SL, Skanderson M, Conigliaro J, Bryant K, Justice AC. Hepatocellular carcinoma and non-Hodgkin's lymphoma: the roles of HIV, hepatitis C infection, and alcohol abuse. J Clin Oncol. 2006 Nov 20;24(33):5005-9. doi: 10.1200/JCO.2006.05.7984.DOI: 10.1200/JCO.2006.05.7984
  • Tate JP, Justice AC, Hughes MD, Bonnet F, Reiss P, Mocroft A, et al. An internationally generalizable risk index for mortality after one year of antiretroviral therapy. AIDS. 2013 Feb 20;27(4):563-72. doi: 10.1097/QAD.0b013e32835c5b67.DOI: 10.1097/QAD.0b013e32835c5b67
  • Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8.DOI: 10.1016/0021-9681(87)90171-8

Related calculators